

Alliance Receives Funding to Conduct Purchaser Discussions

The Alliance received two grants from the National Alliance of Healthcare Purchaser Coalitions to enable purchasers across the country to learn more about two topics:

Biosimilars

Biosimilars, drugs that are similar to already approved biologic drugs, are playing an increasingly important role in prescription drugs. It is estimated that biosimilars will lead to a cost savings of \$54 billion in direct spending on drugs from 2017 to 2026, according to [Rand Corporation](#). This one-time discussion will focus on:

- best practice strategies;
- effective benefit design; and
- including biosimilars in a drug management approach.

Oncology

Cancer treatment advances have caused cancer mortality rate to drop by 25% over a 14-year period, while treatment prices have skyrocketed. The average cost of treating some common cancers now ranges from \$100,000 to \$300,000. These two sessions will focus on the patient journey and:

- prevention and preliminary diagnosis;
- diagnosis, treatment planning and care; and
- survivorship and back to work strategies.

If you are interested in participating in either or both of these roundtable discussions, please contact Director of Membership and Business Engagement [Theresa Lampkin Tamura](#).